Online citations, reference lists, and bibliographies.
← Back to Search

Abundant Expression Of TIM-3, LAG-3, PD-1 And PD-L1 As Immunotherapy Checkpoint Targets In Effusions Of Mesothelioma Patients

E. Marcq, J. Waele, J. V. Audenaerde, E. Lion, E. Santermans, N. Hens, P. Pauwels, J. Van Meerbeeck, E. Smits
Published 2017 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
Malignant pleural mesothelioma (MPM) is an aggressive cancer with an increasing incidence, poor prognosis and limited effective treatment options. Hence, new treatment strategies are warranted which include immune checkpoint blockade approaches with encouraging preliminary data. Research on the immunological aspects of the easily accessible mesothelioma microenvironment could identify prognostic and/or predictive biomarkers and provide useful insights for developing effective immunotherapy. In this context, we investigated the immune cell composition of effusions (pleural and ascites fluids) from 11 different chemotherapy-treated MPM patients. We used multicolor flow cytometry to describe different subsets of immune cells and their expression of immune checkpoint molecules TIM-3, LAG-3, PD-1 and PD-L1. We demonstrate a patient-dependent inter- and intraspecific variation comparing pleural and ascites fluids in immune cell composition and immune checkpoint expression. We found CD4+ and CD8+ T cells, B cells, macrophages, natural killer cells, dendritic cells and tumor cells in the fluids. To the best of our knowledge, we are the first to report TIM-3 and LAG-3 expression and we confirm PD-1 and PD-L1 expression on different MPM effusion-resident immune cells. Moreover, we identified two MPM effusion-related factors with clinical value: CD4+ T cells were significantly correlated with better response to chemotherapy, while the percentage of PD-L1+ podoplanin (PDPN)+ tumor cells is a significant prognostic factor for worse outcome. Our data provide a basis for more elaborate research on MPM effusion material in the context of treatment follow-up and prognostic biomarkers and the development of immune checkpoint-targeted immunotherapy.
This paper references
10.4049/jimmunol.1002050
MHC Class II Engagement by Its Ligand LAG-3 (CD223) Contributes to Melanoma Resistance to Apoptosis
Patrice Hémon (2011)
10.1038/415536a
Th1-specific cell surface protein Tim-3 regulates macrophage activation and severity of an autoimmune disease
L. Monney (2002)
10.1146/annurev-publhealth-031811-124704
The worldwide pandemic of asbestos-related diseases.
L. Stayner (2013)
10.1016/j.lungcan.2016.04.015
Precision immunotherapy; dynamics in the cellular profile of pleural effusions in malignant mesothelioma patients.
L. Lievense (2017)
10.1164/rccm.201203-0465PP
Malignant pleural effusion: tumor-host interactions unleashed.
G. Stathopoulos (2012)
10.1111/cas.13190
Podoplanin promotes progression of malignant pleural mesothelioma by regulating motility and focus formation
Shinji Takeuchi (2017)
10.1007/s00262-010-0881-6
CD8+ tumor-infiltrating lymphocytes predict favorable prognosis in malignant pleural mesothelioma after resection
N. Yamada (2010)
10.1007/82_2010_114
LAG-3 in Cancer Immunotherapy.
Monica V. Goldberg (2011)
10.1186/1471-2407-13-324
Defect in recruiting effector memory CD8+ T-cells in malignant pleural effusions compared to normal pleural fluid
A. Scherpereel (2013)
10.1084/JEM.176.2.327
Characterization of the lymphocyte activation gene 3-encoded protein. A new ligand for human leukocyte antigen class II antigens
E. Baixeras (1992)
10.1002/eji.200323382
The CD4‐related molecule, LAG‐3 (CD223), regulates the expansion of activated T cells
C. Workman (2003)
10.1016/j.jtho.2016.07.033
Malignant Mesothelioma Effusions Are Infiltrated by CD3+ T Cells Highly Expressing PD‐L1 and the PD‐L1+ Tumor Cells within These Effusions Are Susceptible to ADCC by the Anti–PD‐L1 Antibody Avelumab
Swati Khanna (2016)
10.3109/9781439802014-13
Malignant mesothelioma.
B. Robinson (2005)
10.3892/or.2013.2225
Podoplanin overexpression in human mesothelioma cell lines enhances the tumorigenic phenotype.
Ei Yamaki (2013)
CD4 T cells: fates, functions, and faults. Blood
J Zhu (2008)
10.1111/j.1600-065X.2010.00923.x
The PD‐1 pathway in tolerance and autoimmunity
Loise M. Francisco (2010)
10.4049/jimmunol.0901060
Dual Control of Antitumor CD8 T Cells through the Programmed Death-1/Programmed Death-Ligand 1 Pathway and Immunosuppressive CD4 T Cells: Regulation and Counterregulation1
A. Currie (2009)
10.1016/j.jtho.2016.06.021
Pleural Effusion of Patients with Malignant Mesothelioma Induces Macrophage‐Mediated T Cell Suppression
L. Lievense (2016)
10.1183/16000617.0019-2016
Malignant pleural effusion: from bench to bedside
I. Psallidas (2016)
10.1155/2012/927240
New Roads Open Up for Implementing Immunotherapy in Mesothelioma
R. Cornelissen (2012)
10.1097/JTO.0000000000000177
B7-H1 Expression in Malignant Pleural Mesothelioma is Associated with Sarcomatoid Histology and Poor Prognosis
A. Mansfield (2014)
10.1371/journal.pone.0121071
Analysis of Expression of Programmed Cell Death 1 Ligand 1 (PD-L1) in Malignant Pleural Mesothelioma (MPM)
S. Cedrés (2015)
10.1056/NEJMRA050152
Advances in malignant mesothelioma.
B. Robinson (2005)
10.1016/S1470-2045(13)70381-4
Tremelimumab for patients with chemotherapy-resistant advanced malignant mesothelioma: an open-label, single-arm, phase 2 trial.
L. Calabrò (2013)
10.1007/s11864-011-0149-1
Novel Targeted Therapies and Vaccination Strategies for Mesothelioma
M. Bagia (2011)
10.1158/0008-5472.CAN-05-4303
Tumor B7-H1 is associated with poor prognosis in renal cell carcinoma patients with long-term follow-up.
R. H. Thompson (2006)
10.4049/jimmunol.174.2.688
Negative Regulation of T Cell Homeostasis by Lymphocyte Activation Gene-3 (CD223)1
C. Workman (2005)
10.1016/j.canlet.2012.02.034
Immunity and malignant mesothelioma: from mesothelial cell damage to tumor development and immune response-based therapies.
V. Izzi (2012)
10.1016/S1470-2045(17)30169-9
Clinical safety and activity of pembrolizumab in patients with malignant pleural mesothelioma (KEYNOTE-028): preliminary results from a non-randomised, open-label, phase 1b trial.
E. Alley (2017)
10.1200/JCO.2016.34.15_SUPPL.8503
Avelumab (MSB0010718C; anti-PD-L1) in patients with advanced unresectable mesothelioma from the JAVELIN solid tumor phase Ib trial: Safety, clinical activity, and PD-L1 expression.
R. Hassan (2016)
10.1182/blood-2011-06-360321
Tim-3 is an inducible human natural killer cell receptor that enhances interferon gamma production in response to galectin-9.
M. Gleason (2012)
10.1097/CJI.0b013e31825898c5
Tumor-specific CD4+ Melanoma Tumor-infiltrating Lymphocytes
K. Friedman (2012)
Cisplatininduced antitumor immunomodulation: a review of preclinical and clinical evidence
AR de Biasi (2014)
10.1097/CJI.0b013e318183af0b
Immunization With Analog Peptide in Combination With CpG and Montanide Expands Tumor Antigen-specific CD8+ T Cells in Melanoma Patients
J. Fourcade (2008)
10.1371/journal.pone.0167186
Diagnostic Utility of Pleural Fluid Cell Block versus Pleural Biopsy Collected by Flex-Rigid Pleuroscopy for Malignant Pleural Disease: A Single Center Retrospective Analysis
Shion Miyoshi (2016)
10.1073/pnas.0611533104
Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer
J. Hamanishi (2007)
10.1002/dc.21340
Podoplanin is a useful marker for identifying mesothelioma in malignant effusions
Atef N Hanna (2010)
10.1126/science.1148536
Promotion of Tissue Inflammation by the Immune Receptor Tim-3 Expressed on Innate Immune Cells
A. Anderson (2007)
10.1016/j.jtho.2016.06.022
Pleural Effusions from Patients with Mesothelioma Induce Recruitment of Monocytes and Their Differentiation into M2 Macrophages
Anne-Laure Chéné (2016)
10.1182/blood-2008-05-078154
CD4 T cells: fates, functions, and faults.
J. Zhu (2008)
10.1111/j.1365-2567.2005.02145.x
The negative regulatory function of the lymphocyte‐activation gene‐3 co‐receptor (CD223) on human T cells
L. Maçon-Lemaître (2005)
10.1016/j.ctrv.2015.09.006
Targeting immune checkpoints: New opportunity for mesothelioma treatment?
E. Marcq (2015)
10.1080/2162402X.2016.1261241
Prognostic and predictive aspects of the tumor immune microenvironment and immune checkpoints in malignant pleural mesothelioma
E. Marcq (2017)
10.1002/cncr.24899
Tumor cell expression of programmed cell death‐1 ligand 1 is a prognostic factor for malignant melanoma
R. Hino (2010)
10.1200/JCO.2014.32.15_SUPPL.TPS7609
Randomized, double-blind, placebo-controlled study of tremelimumab for second- and third-line treatment of unresectable pleural or peritoneal mesothelioma.
M. Maio (2014)
10.1093/jnci/djq310
Improved Endpoints for Cancer Immunotherapy Trials
A. Hoos (2010)
Microenvironment and Immunology Anti-TIM 3 Antibody Promotes T Cell IFN-g – Mediated Antitumor Immunity and Suppresses Established Tumors
S. Ngiow (2011)
A phase II study of Nivolumab in malignant pleural mesothelioma (NIVOMES): with translational research (TR) biopsies
JQ Janssen (2017)
10.1111/j.1440-1827.2005.01791.x
Podoplanin as a marker for mesothelioma
Noriko Kimura (2005)
10.1200/JCO.2003.11.136
Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma.
N. Vogelzang (2003)
10.1200/JCO.20005.14.589
Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an intergroup study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada.
J. Van Meerbeeck (2005)
10.1016/j.cytogfr.2012.08.009
The emerging role of T cell cytokines in non-small cell lung cancer.
M. Neurath (2012)
10.1200/JCO.2014.32.15_SUPPL.7531
A phase 2 single-arm study with tremelimumab at an optimized dosing schedule in second-line mesothelioma patients.
L. Calabrò (2014)
10.1002/1097-0142(19840201)53:3<377::AID-CNCR2820530302>3.0.CO;2-B
Malignant mesothelioma. The university of minnesota experience
N. Vogelzang (1984)



This paper is referenced by
10.1016/j.jtho.2019.03.029
Potential Diagnostic and Prognostic Role of Microenvironment in Malignant Pleural Mesothelioma.
I. C. Salaroglio (2019)
10.21037/tlcr.2019.11.23
Immunotherapy for mesothelioma: a critical review of current clinical trials and future perspectives.
S. Gray (2020)
10.1007/s00262-019-02475-w
Immune profile and immunosurveillance in treatment-naive and neoadjuvantly treated esophageal adenocarcinoma
Svenja Wagener-Ryczek (2020)
10.1158/2326-6066.CIR-18-0054
Immune-Checkpoint Blockade Opposes CD8+ T-cell Suppression in Human and Murine Cancer
Lukas W. Pfannenstiel (2019)
10.18632/genesandcancer.180
The promising immune checkpoint LAG-3: from tumor microenvironment to cancer immunotherapy
L. Long (2018)
10.1080/2162402X.2018.1554969
Making cold malignant pleural effusions hot: driving novel immunotherapies
Pranav Murthy (2019)
10.1126/scitranslmed.aat7807
The hallmarks of successful anticancer immunotherapy
L. Galluzzi (2018)
10.3390/cancers12040915
Fully Human Antibodies for Malignant Pleural Mesothelioma Targeting
Fabio Nicolini (2020)
10.1186/s13104-018-3953-x
Tumour associated lymphocytes in the pleural effusions of patients with mesothelioma express high levels of inhibitory receptors
Jonathan Chee (2018)
10.3389/fonc.2019.01366
The Immune Microenvironment in Mesothelioma: Mechanisms of Resistance to Immunotherapy
G. Chu (2019)
Immunotherapy for mesothelioma: rationale and new approaches.
Joshua E Reuss (2020)
FFPE Formalin-fixed and paraffin embedded FLOT FLOT-trial regimen with 5FU, Folinic acid, Oxaliplatin, Docetaxel H&E Hematoxylin–eosin HAVCR2 Hepatitis A virus cellular receptor 2 HER2 Human epidermal growth factor receptor 2 HLA Human histocompatibility leukocyte Ag IDO Indoleamine-pyrrole
Schoemmel (2020)
10.1002/ijc.32363
NK‐ and T‐cell subsets in malignant mesothelioma patients: Baseline pattern and changes in the context of anti‐CTLA‐4 therapy
Rosa Sottile (2019)
10.3389/fimmu.2018.02493
Engineering CAR-T Cells for Improved Function Against Solid Tumors
M. Morgan (2018)
10.1007/978-3-030-16884-1_5
Microenvironment and Immunology of the Human Pleural Malignant Mesothelioma
Elisabeth Digifico (2019)
10.1007/s00262-019-02403-y
PTPN3 expressed in activated T lymphocytes is a candidate for a non-antibody-type immune checkpoint inhibitor
A. Fujimura (2019)
Semantic Scholar Logo Some data provided by SemanticScholar